Search

A patent application titled "Pharmaceutical Composition Of Anti-Angptl3 Antibody Or Antigen Binding Fragment Thereof And Its Application" was published online on October 24, 2024, by inventors from Lianyungang, China. The application focuses on developing stable formulations of anti-ANGPTL3 antibodies to treat hyperlipidemia by inhibiting lipoprotein metabolism and promoting triglyceride degradation. The pharmaceutical composition includes specific buffer solutions, antibody sequences, and concentrations to ensure stability and efficacy in treating diseases like hyperlipidemia, cardiovascular disorders, cancer, and inflammatory conditions. The patent application provides detailed information on the composition, preparation methods, and therapeutic applications of the anti-ANGPTL3 antibodies. [Extracted from the article]

The patent application titled "Anti-Cd73 Antibodies And Uses Thereof" discusses the development of antibodies targeting CD73, a protein involved in cancer progression. The inventors have identified specific amino acid sequences for the antibodies that bind to CD73, potentially offering a new therapeutic approach for cancer treatment. The application also outlines methods for producing these antibodies, as well as their potential use in treating various types of cancer with high adenosine signatures. This research highlights the ongoing efforts to develop innovative immunotherapies for cancer treatment. [Extracted from the article]

The patent application titled "Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules that Bind CD3 and CD20, and Uses Thereof" discusses the development of antibodies that target CD3 and CD20 proteins for therapeutic purposes. CD3 is crucial for T cell activation, while CD20 is expressed on B cells and is a target for cancer treatment. The patent application details the amino acid sequences and nucleic acid molecules involved in creating these antibodies, emphasizing their potential in targeted therapy. [Extracted from the article]

Researchers have submitted a patent application for a novel cell therapy involving engineered cells that secrete a multispecific antibody targeting B cell maturation antigen (BCMA). This therapy aims to induce host T cells to attack BCMA-expressing cells, potentially benefiting patients with various cancers, autoimmune diseases, and allergic disorders. The patent application outlines the development of anti-BCMA, anti-CD3 bispecific antibodies and their potential therapeutic applications, emphasizing improved target engagement and safety compared to existing treatments. The innovative approach described in the patent application offers a promising new strategy for targeting BCMA+ cells for therapeutic purposes. [Extracted from the article]

Researchers have submitted a patent application for an "ANTI-CD79BxCD3 BISPECIFIC ANTIBODY" to address the need for improved therapies against B-cell non-Hodgkin's lymphoma. The antibody binds to CD79b and CD3 with high specificity and affinity, allowing T cells to target tumor cells expressing CD79b. This development in bispecific antibody-based immunotherapies shows promise in enhancing efficacy and safety compared to existing treatments. The patent application was filed by Innovent Biologics (Suzhou) Co. Ltd. in China, reflecting advancements in biotechnology and healthcare biotechnology companies in Asia. [Extracted from the article]

Researchers have submitted a patent application for "Pipelines For Tumor Immunophenotyping" to the USPTO. The application focuses on techniques for determining a tumor immunophenotype based on digital pathology images, aiming to improve the accuracy of tumor immunophenotype classification. By standardizing the assessment of immune effector cells in the tumor microenvironment, these pipelines could enhance the efficacy of immunotherapies and potentially increase patient survival rates. The methodologies described in the patent application utilize varying levels of granularity and may involve machine learning models to automate certain steps in the process. [Extracted from the article]

A patent application titled "Bispecific T cell Engagers" was published online by inventors from Newbury Park, CA, on October 17, 2024. The application focuses on developing treatments for cancer using antibodies that target specific proteins expressed in cancer cells, such as DLL3, MUC17, and CLD18. These bispecific molecules aim to activate T cells to attack and kill tumor cells, potentially offering more targeted and effective cancer therapies with fewer side effects than conventional treatments like chemotherapy and radiation therapy. The patent application outlines various aspects of the invention, including monoclonal antibodies, bispecific molecules, and methods for treating cancer using these innovative therapies. [Extracted from the article]

Researchers from Blueprint Medicines Corporation have identified and optimized STK17B kinase inhibitors that enhance T cell responses in vitro and in vivo, potentially offering a new approach for cancer immunotherapy. The study developed highly potent and selective small molecule inhibitors targeting STK17B, leading to increased T cell activation and antitumor activity in mouse models. This research highlights the potential of STK17B inhibition as a promising strategy for cancer treatment. [Extracted from the article]

Researchers from University Hospital Nantes have conducted a literature review and case report on bleeding management in type 3 von Willebrand disease with anti-von Willebrand factor inhibitor. The study found that treatment with von Willebrand factor and factor VIII concentrates can lead to the development of anti-VWF antibodies, complicating haemostasis management. The research highlighted the use of emicizumab as a therapeutic option in cases of allo-immunisation, showcasing its effectiveness in controlling bleeding in complex situations. This study provides valuable insights into managing this rare inherited blood coagulation disorder. [Extracted from the article]

A recent report from the Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses the potential of Siglec-8-directed immunotherapy for eosinophilic and mast cell disorders. The study highlights the development of fully human monoclonal antibodies that show promise in delivering cytotoxic payloads to target cells expressing Siglec-8. These findings suggest that Siglec-8-directed immunotherapies could be highly potent and may offer new treatment options for these challenging disorders. For more information, the full article is available in Cancers journal. [Extracted from the article]

A patent has been issued for a trispecific antibody targeting CD79b, CD20, and CD3 by Janssen Biotech Inc. The antibody aims to address unmet medical needs in patients with B-cell malignancies, particularly those with relapsed or refractory non-Hodgkin lymphoma. By targeting multiple antigens simultaneously, this novel therapeutic approach shows promise in improving treatment outcomes for patients with B-cell malignancies. The patent details the structure and function of the trispecific antibody, highlighting its potential applications in cancer treatment and diagnosis. [Extracted from the article]

The patent issued for T cell activating bispecific antigen binding molecules by F. Hoffmann-La Roche Inc. focuses on developing antibodies that can activate immune cells to target and destroy specific cells, such as tumor cells, without harming healthy tissues. Various formats of bispecific antibodies, such as BiTEs, diabodies, DART molecules, and triomabs, are being explored for T cell engagement in immunotherapy. The patent aims to address challenges related to the efficacy, toxicity, applicability, and production of bispecific antibodies for T cell-mediated immunotherapy, highlighting the need for novel and improved formats of such molecules. [Extracted from the article]

Research from F. Hoffmann-La Roche - Roche Pharma Research and Early Development explores the use of bispecific antibodies in cancer immunotherapy. The study focuses on the impact of binding affinity on trimeric complex formation and pharmacology, using mathematical modeling and simulation. The findings suggest that optimizing binding affinities can enhance the effectiveness of cancer immunotherapy, particularly in solid tumor indications like colon cancer. This research provides a valuable framework for selecting binding affinities for bispecific antibodies, potentially increasing the success rate of cancer immunotherapy in clinical development. [Extracted from the article]

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to LBL-024, a bispecific antibody developed by Leads Biolabs, for the treatment of advanced extrapulmonary neuroendocrine carcinoma (EP-NEC) patients who have not responded to previous chemotherapy. This designation recognizes LBL-024's significant clinical efficacy and safety profile, with data showing improved Objective Response Rate (ORR) and Overall Survival (OS) compared to existing treatments. The Breakthrough Therapy Designation aims to accelerate the approval process and provide new treatment options for patients with life-threatening conditions, reflecting China's commitment to innovative drug development. [Extracted from the article]

Researchers from the University of Texas System have submitted a patent application for "Cd3-Expressing Natural Killer Cells With Enhanced Function For Adoptive Immunotherapy." This application focuses on modifying natural killer (NK) cells to express CD3 receptors and T-cell receptors, allowing for improved immunotherapies targeting cancer antigens. The patent aims to enhance the effectiveness of adoptive cell therapy by combining modified NK cells with antibodies that can activate and kill target cells, providing a promising approach for cancer treatment. The research highlights the potential of engineered NK cells in conjunction with bispecific antibodies to enhance cytotoxicity against cancer cells, offering new possibilities for cancer immunotherapy. [Extracted from the article]

Researchers at University Hospital Wurzburg in Germany are exploring new immunotherapeutic strategies for treating Diffuse Large B-cell Lymphoma (DLBCL). They are investigating the use of anti-CD19 CAR T-cell therapies, bispecific antibodies, and other immunotherapies to enhance treatment options for patients who cannot tolerate traditional therapies. By combining innate and adaptive immune responses, researchers aim to overcome resistance to current immunotherapies and reprogram the immunosuppressive tumor microenvironment of DLBCL. This research, supported by Incyte Corporation and MorphoSys AG, highlights the potential for future DLBCL treatment approaches through innovative immunotherapy techniques. [Extracted from the article]

Janssen Biotech Inc. has been issued a patent for methods of treating cancers and enhancing the efficacy of BCMAxCD3 bispecific antibodies. The patent describes a method of treating multiple myeloma, a type of cancer, by administering a combination of a BCMAxCD3 bispecific antibody and an anti-CD38 antibody. The method involves subcutaneously administering the antibodies in specific doses over treatment cycles. The invention aims to provide a new treatment option for relapsed or refractory multiple myeloma patients who have already been exposed to standard therapies. [Extracted from the article]

A recent report from Michigan State University College of Human Medicine highlights the effectiveness of teclistamab, a bispecific antibody, in treating pericardial effusion in patients with relapsed multiple myeloma. Pericardial involvement is a rare manifestation of multiple myeloma, and there have been few documented cases of pericardial effusion as an extramedullary relapse presentation. The use of bispecific antibodies, such as teclistamab, has shown great effectiveness in treating relapsed refractory multiple myeloma, including cases with extramedullary disease. This research provides valuable insights into the potential of immunotherapy drugs for the treatment of multiple myeloma. [Extracted from the article]

A patent has been issued for a composition and method for diagnosing and treating iron-related disorders. The patent describes an isolated antibody or antibody fragment that binds to Repulsive Guidance Molecule c (RGMc) and provides detailed amino acid sequences for the antibody. The composition includes a variable heavy chain region and a variable light chain region, and it may be in a lyophilized or solution form. The patent was filed by AbbVie Deutschland GmbH & Co. KG and published online on September 24, 2024. This information may be useful for library patrons conducting research on health and medicine, immunology, and diagnostics and screening. [Extracted from the article]

This document is a patent for a composition and method for the diagnosis and treatment of iron-related disorders. The patent describes an isolated antibody or antibody fragment that can be used to inhibit the activity of RGMc, a protein involved in iron metabolism. The antibody or antibody fragment can be a monoclonal antibody, a humanized antibody, or a human antibody. The patent also includes claims for methods of administering the antibody to subjects with anemia of chronic disease or anemia of chronic kidney disease, resulting in the inhibition of RGMc activity and the modulation of iron metabolism. [Extracted from the article]

A study conducted at JSS College of Pharmacy in Mysuru, India, explores the use of HER2-targeted therapies in cancer treatment. The study highlights the development of monoclonal antibodies like Trastuzumab and Pertuzumab, which have shown significant benefits in cancer therapy. Researchers have also developed bispecific antibodies and antibody-drug conjugates to overcome resistance associated with monotherapy. The study provides a comprehensive understanding of HER2-targeted strategies in cancer treatment, including the structural characteristics of HER2, the HER family signaling pathway mechanism, and recent findings regarding HER2 receptor involvement in various cancers. [Extracted from the article]

A patent application has been published online for a method of treating diffuse large B-cell lymphoma (DLBCL) using a combination therapy. DLBCL is a common type of non-Hodgkin lymphoma, and current treatments have limited effectiveness for high-risk patients. The method involves administering a bispecific antibody along with a standard treatment regimen in 21-day cycles. Different dosing schedules are provided depending on the specific treatment regimen, and the treatment continues until certain response criteria are met or until disease progression or unacceptable toxicity occurs. The method is applicable to different types of DLBCL and patients with specific prognostic scores. [Extracted from the article]

A patent has been issued to Exelixis Inc. for anti-ROR antibody constructs. These constructs are designed to bind to tyrosine-protein kinase transmembrane receptor (ROR) antigens, which are found on certain tumor cells. The antibody constructs have the potential to provide targeted therapy for cancer by recruiting and redirecting T cells to kill ROR-expressing cancer cells. The patent describes the amino acid sequences and arrangements of the antibody binding sites, as well as their potential applications in treating various types of cancer. [Extracted from the article]

Beijing Mabworks Biotech Co. Ltd. has been issued a patent for antibodies that target B cell maturation antigen (BCMA) and CD3, which are potential targets for multiple myeloma treatment. The antibodies have the potential to recruit T cells to cancer sites and induce cancer cell death. The patent describes the construction of antibodies with high BCMA binding affinity and lower adverse side effects. It also includes claims related to nucleic acid molecules encoding these antibodies, pharmaceutical compositions containing them, and methods of using them to treat BCMA-associated diseases. The patent provides detailed information about the specific sequences and compositions involved. [Extracted from the article]

A patent application titled "Improving Antibody Tolerability Associated With Intravenous Administration" has been published online by the US Patent and Trademark Office. The patent application, filed by inventors from Bioinvent International AB, describes a method for administering therapeutic antibodies that reduces or prevents infusion-related reactions (IRRs) in patients. The method involves administering multiple doses of the antibody, including an initial sub-maximal dose after the patient has received a corticosteroid. The inventors have also developed a method to predict if a therapeutic antibody will cause tolerability issues and to identify ways to prevent or mitigate these issues. This patent application addresses the need for methods to improve the tolerability of intravenous antibody administration and provides a potential solution for reducing IRRs in patients. [Extracted from the article]

A patent has been issued to the University of Oklahoma for anti-DCLK1 antibodies and chimeric antigen receptors, along with their compositions and methods of use. The patent describes the use of DCLK1 as a target for the treatment of cancer, particularly solid tumors that express or overexpress DCLK1. The invention involves the development of isolated, humanized antibodies that bind to DCLK1 and can be used diagnostically and therapeutically. This patent provides potential advancements in the safe and effective treatment of cancer, specifically solid tumors. [Extracted from the article]

The USPTO has published a patent application titled "Anti-Cd3 Multispecific Antibodies And Methods Of Use" by inventors from China. The application discusses the development of CD3-bispecific antibodies for cancer immunotherapy, which have the potential to activate T cells and induce anti-tumor immune responses. It provides detailed information on the structure, characteristics, and potential use of these antibodies in treating various types of cancer. The patent also covers pharmaceutical compositions containing the antibodies and methods for their production. This information may be valuable to researchers and individuals studying cancer treatment and immunology. [Extracted from the article]

The patent application titled "Recombinant Proteinaceous Binding Molecules" discusses the development of bispecific antibodies and chimeric antigen receptor (CAR) T cells for cancer immunotherapy. It explains that bispecific antibodies have two binding sites and can recruit cytotoxic T cells to target tumors, while CAR T cells are genetically modified to target tumor antigens. Both have shown promise in clinical trials, but there are limitations. The application describes a recombinant proteinaceous binding molecule that combines a binding moiety, antibody variable domain, and altered Fc fragment to enhance binding capabilities. This molecule has potential therapeutic applications, particularly in cancer treatment. [Extracted from the article]

The US Patent and Trademark Office is currently reviewing a patent application titled "Anti-Mesothelin Antigen-Binding Molecules And Uses Thereof." The application discusses the development of antibodies and polypeptides that target mesothelin, a protein found in certain tumors. These antibodies, including bispecific antibodies that also bind to CD3, a T cell antigen, have potential therapeutic applications in killing tumor cells. The application provides detailed information about the amino acid sequences and characteristics of these antibodies, as well as their potential use in treating tumors. This information may be valuable to researchers studying peptides, immunology, amino acids, blood proteins, and bispecific antibodies. [Extracted from the article]

A recent study conducted by the Medical College of Wisconsin examined the association between immune prognostic scores and outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies. The study found that patients with high-risk CAR-HEMATOTOX scores had a higher incidence of infections and inferior survival, suggesting the need for aggressive infection mitigation strategies. However, patients identified as high risk based on the Glasgow prognostic score did not experience increased toxicity or mortality. This research provides valuable insights into the use of bispecific antibodies in the treatment of multiple myeloma. [Extracted from the article]

Chugai Seiyaku Kabushiki Kaisha has submitted a patent application for a cytotoxicity-inducing therapeutic agent that aims to treat cancer by utilizing T cells' cytotoxicity against cancer cells. The invention involves the development of polypeptide complexes that have a long half-life in the blood and do not cause adverse effects like cytokine storm. The patent application provides details about the structure and composition of these complexes and their potential use in pharmaceutical compositions for cancer treatment. Specifically, it describes a bispecific antibody with two antigen-binding domains, one binding to CD3 and the other to CD20, and a modified Fc region. This modified antibody has potential applications in cancer therapy and immunotherapy. For more information, please consult the full patent application. [Extracted from the article]

A patent has been issued for a method of treating HER2-positive, hormone receptor-positive breast cancer using a combination of drugs. The method involves administering a bispecific anti-HER2 antigen-binding construct, palbociclib, and fulvestrant. The goal of the treatment is to achieve a complete or partial response or stable disease in patients, and it can be used as a second or third-line therapy. The patent also mentions the potential for combining the treatment with other chemotherapies or gonadotropin-releasing hormone analogues. [Extracted from the article]

This document is a patent for a pharmaceutical composition that aims to deliver and retain substances in cartilage tissue. The invention includes a polypeptide with an aggrecan-binding domain linked to a carrying moiety, which can release the antigen binding polypeptide. The patent also covers the use of the polypeptide and an anti-aggrecan antibody in treating aggrecan-associated diseases and disorders, such as osteoarthritis. The document provides detailed claims and sequences related to the invention. [Extracted from the article]

A recent study from Mayo Clinic in Jacksonville, Florida, discusses the incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The study highlights the challenges in treating BCP-ALL in adults, as remission rates are still lower compared to the pediatric population, and the risk of relapse remains high. However, the use of immunotherapeutic agents, such as rituximab, inotuzumab ozogamicin, blinatumomab, and CAR T-cells, has shown promising results in improving response and decreasing relapse without increasing toxicity. The study emphasizes the evolution of chemoimmunotherapy-based treatment approaches in managing treatment-naive BCP-ALL. [Extracted from the article]

A recent study from Shandong University in China provides an update on antibody-drug conjugates (ADCs) for hematological malignancies. ADCs are a type of tumor immunotherapy that combines monoclonal antibodies with cytotoxic drugs. The study highlights the challenges faced by ADCs, such as adverse effects, drug resistance, tumor targeting, and payload release. The researchers suggest optimizing the individual components of ADCs, exploring new targets and payloads, and using bispecific antibodies to increase precision. The review also discusses the progress of ADC research, the potential for combining ADCs with other chemotherapeutic agents, and the future directions for improving their efficacy in the treatment of hematological malignancies. [Extracted from the article]

A recent report discusses research findings on cancer therapy from the Instituto de Investigacion Sanitaria de Navarra. The researchers explored different approaches to overcome xenograft-versus-host disease (xGVHD) in immunodeficient mice engrafted with peripheral blood mononuclear cells (PBMCs), which is a model used to study new cancer immunotherapy agents. They evaluated strategies such as immune graft modification, cyclophosphamide administration, and the use of major histocompatibility complex (MHC) class I and II-deficient mice. The study found that MHC-dKO immunodeficient mice allow for the preclinical testing of immunotherapy agents that cannot be tested in conventional immunodeficient mice due to severe xGVHD. [Extracted from the article]

The European Society for Blood and Marrow Transplantation (EBMT) has reached a significant milestone by registering 10,000 patients who have received chimeric antigen receptor T-cell (CAR-T) therapy. CAR-T therapy is a personalized medicine that is administered in one treatment and has shown promise in the treatment of haematological malignancies. The EBMT Registry, established in 1974, provides data to healthcare professionals to improve the care of patients with haematological malignancies and other life-threatening disorders. The registry contains data on over 700,000 patients who have received a hematopoietic cell transplantation procedure and over 10,000 patients who have received CAR-T therapy. [Extracted from the article]

A patent application titled "Methods And Compositions For Treating Cancer" has been published online, discussing the need for new therapeutic approaches in the treatment of esophageal cancer, melanoma, B cell proliferative disorders, and colorectal cancer. The application outlines different dosing regimens involving antibodies and bispecific antibodies to achieve positive outcomes in patients with these types of cancer. The methods described in the application aim to address the lack of effective immunotherapies currently available for these populations. The application provides comprehensive information on the dosing regimens and specific combinations of antibodies used in the treatments. [Extracted from the article]

A patent application has been filed for genetically modified non-human animals that have been altered to produce human-like antibodies. These animals have specific genetic modifications that allow them to produce antibodies that can bind to antigens. The purpose of this patent application is to provide efficient and cost-effective methods for producing these humanized antibodies, which can be used for various research and treatment purposes. The application also includes methods for making these antibodies and the antibodies themselves. [Extracted from the article]

A study conducted by researchers at Seattle Children's Research Institute explores the use of bispecific antibodies for the treatment of acute leukemias. The study focuses on the secretion of bispecific antibodies by human plasma cells and their effectiveness in killing leukemia cells. The researchers found that plasma cells secreting anti-CD19-bispecific antibodies were able to control acute lymphoblastic leukemia in mice. The study suggests that engineered plasma cells could be a promising delivery system for the treatment of acute leukemias and potentially other cancers. [Extracted from the article]

A recent study conducted by researchers at Scancell Ltd. in Nottingham, United Kingdom, has identified a potential treatment option for small-cell lung cancer (SCLC). The researchers developed a bispecific antibody called SC134-TCB, which targets a glycolipid called Fucosyl-GM1 (FucGM1) that is overexpressed in SCLC tumors. In preclinical models, SC134-TCB demonstrated potent anti-tumor activity, effectively activating T cells and resulting in tumor-free survival in a human PBMC admixed setting. Combination treatment with Atezolizumab further enhanced survival and tumor growth inhibition. These findings suggest that SC134-TCB could be a promising immunotherapy treatment option for SCLC patients. [Extracted from the article]

A recent report from University Hospital Heidelberg in Germany discusses the potential use of tebentafusp, a bispecific fusion protein, in the treatment of metastatic uveal melanoma. The protein targets gp100, an antigen expressed in uveal melanoma cells, and redirects T cell-mediated cytotoxicity towards tumor cells. Preclinical studies have shown promising results, with tebentafusp inducing potent anti-tumor immune responses. Clinical trials have also demonstrated meaningful clinical activity in some patients with metastatic uveal melanoma. The researchers are also exploring the potential of T cell engagers targeting the cancer testis antigen PRAME for the treatment of cutaneous melanoma and other PRAME-expressing malignancies. [Extracted from the article]

A recent study conducted by researchers at the University of Ostrava in the Czech Republic has explored the characteristics of extramedullary disease (EMD) in multiple myeloma (MM). EMD is a high-risk feature of MM and remains a poor prognostic factor, even with the use of novel immunotherapies. The study utilized spatial transcriptomics and single-cell RNA sequencing to analyze the three-dimensional architecture of tumor cells and their microenvironment in EMD biopsies. The researchers found significant heterogeneity within plasma cells at the copy number level, as well as spatial expression differences of important antigens for bispecific antibody therapy. The study also revealed the presence of various immune cells, including T-cells, within EMD masses. Notably, exhausted T-cells were found to co-localize with MM cells, while functional and activated T-cells showed a focal infiltration pattern. The researchers concluded that spatial transcriptomics has unveiled a complex multicellular ecosystem in EMD, highlighting the potential for checkpoint inhibition and dual targeting as new therapeutic approaches. [Extracted from the article]

The US Patent and Trademark Office has published a patent application titled "Therapeutic Targeting Of Cadherin 11 In Cancer," which proposes the use of anti-Cadherin 11 (CDH11) antibodies and immunoconjugates for the treatment and detection of cancer. The method involves administering an antibody that binds to CDH11 to treat or delay the progression of cancer, and also includes methods for detecting the presence of circulating tumor cells and diagnosing cancer. The invention aims to develop effective immunotherapies to address the burden of cancer. The patent application discusses the specific amino acid sequences of the CDH11 antibody and its potential use for localized or metastatic cancers, such as breast or pancreatic cancer, in combination with other therapies. Additionally, the application describes methods for detecting circulating tumor cells and diagnosing cancer using the CDH11 antibody. [Extracted from the article]

This document is a patent application for "Anti-Muc16 Antibodies" that specifically target the truncated portion of MUC16 found on the surface of cancer cells. The patent describes an antibody or binding fragment that can inhibit tumor growth in cancers expressing MUC16. The antibody can be used to treat autoimmune diseases, inflammatory diseases, and various types of cancer cells, including ovarian, breast, prostate, colon, lung, brain, pancreatic, kidney, fallopian tube, uterine, and primary peritoneum cancer cells. The patent application provides detailed information about the amino acid sequences and structures of the antibodies. [Extracted from the article]

Chugai Seiyaku Kabushiki Kaisha has submitted a patent application for a cytotoxicity-inducing therapeutic agent that aims to treat cancer by utilizing the cytotoxicity of T cells against cancer cells. The invention describes polypeptide complexes that have a long half-life in the blood and do not cause adverse effects. These complexes include antibodies with specific amino acid substitutions that bind to CD3 and CD20, reducing their ability to bind to a specific human Fcg receptor. The patent application provides detailed information about the structure, composition, and potential use of these polypeptide complexes in cancer treatment. [Extracted from the article]

A patent has been issued for compositions comprising antigen-binding molecules, specifically antibodies, that have reduced side effects and are more specific for disease cells. The patent describes a combination of antigen-binding molecules that form a bispecific antibody on the target cell surface, reducing side effects. The patent includes specific embodiments of the invention and claims for the antigen-binding molecules, which are composed of two polypeptides with antigen-binding and IgG Fc domains. The patent also includes various substitutions in the polypeptides' domains and provides a method for testing the composition. The patent was filed by Tomoyuki Igawa and assigned to Chugai Seiyaku Kabushiki Kaisha. [Extracted from the article]

This patent application discusses the development of PD-L1xCD28 bispecific antibodies for immune checkpoint-dependent T cell activation. The invention aims to enhance the anti-tumor activity of CD28 bispecific antibodies by replacing the anti-tumor-associated antigen (TAA) targeting arm with an antibody arm that has intrinsic therapeutic activity, specifically targeting PD-L1. The PD-L1xCD28 bispecific antibodies can provide costimulatory signal 2 to T cells, prevent PD-1/PD-L1 interaction, and prevent PD-L1 from inhibiting CD28 co-stimulatory signal. The patent application provides detailed information on the amino acid sequences of the bispecific antibodies and their compositions. This patent application describes a bispecific antibody that can activate T cells through the binding of Programmed Death-ligand 1 (PD-L1) and CD28. The antibody has specific amino acid sequences in its heavy and light chain variable regions. It can be used to reduce tumor cell proliferation and enhance tumor cell killing, and it may be effective in treating various types of cancer. The antibody can be administered to patients as a composition with a pharmaceutically acceptable carrier. The invention also includes methods for using the antibody to treat cancer and other pathologies. [Extracted from the article]